1. Aurobindo Pharma
Aurobindo Pharma Share Price

Aurobindo Pharma Share Price

NSE: AUROPHARMA

|

BSE: 524804

|

Pharmaceuticals

76% Buy

₹1,100.30

+₹3.10 (0.28%) Last updated on 23 Jun, 2025 | 15:14 IST

Aurobindo Pharma Overview

Market cap
Market Cap Switch₹63,726 Crs
Open
₹1,094.10
Prev. Close
₹1,097.20
Circuit range
₹1,206.90 - ₹987.50
Day range
₹1,087.20 - ₹1,105.40
Year range
₹1,010.00 - ₹1,592.00
Volume
2,78,385
Avg. traded
₹1,097.36
Revenue (12m)
₹31,724 Crs

About Aurobindo Pharma

Founded in 1986 by PV Ramprasad Reddy and K Nityananda Reddy, Aurobindo Pharma is one the largest pharmaceutical companies in India. Its operations began in 1988 with a single unit producing semi-synthetic penicillin (SSP) in Puducherry. The company went public in 1992 and was listed on the stock exchanges in 1995.

The market capitalisation of Aurobindo Pharma Limited is over ₹63,800 crore as of December 28, 2023. Aurobindo Pharma share price has gained over 14% in three years.

Business operations

Aurobindo Pharma specialises in producing semi-synthetic penicillin and has a strong presence in various essential medical areas such as cephalosporins, antivirals, cardiovascular and gastroenterology. It is the leading provider of semi-synthetic penicillin medications. The company's product range covers formulations like those for cardiovascular, gastroenterology, antiretrovirals and anti-infectives.

Notable formulations include trandolapril, captopril, and benazepril hydrochloride, among others. It also manufactures active pharmaceutical ingredients and organic intermediates like desmethyl azithromycin, methenamine and benzimidazole.

Aurobindo Pharma operates 11 units for APIs/intermediates and 15 units (10 in India, three in the USA, one in Brazil and one in Portugal) for formulations, strategically designed to cater to both established and emerging market needs.

In the United States, Aurobindo Pharma operates across oral medications, injectables, over-the-counter and branded oncology segments. It has submitted 774 ANDAs (abbreviated new drug applications) and received 565 final approvals as of March 31, 2023.

In Europe, Aurobindo Pharma has established its presence in 10 countries with fully equipped pharmacies, hospitals, and sales infrastructure for tenders.

Its business model heavily relies on its input. A total of ₹1,411.5 crore was allocated towards research and development (R&D). This initiative led to the submission of 774 Abbreviated New Drug Applications (ANDAs), 276 Drug Master Files (DMFs) and 813 filed patent applications. The company filed 4,359 formulation dossiers and 3,718 API (Active Pharmaceutical Ingredient) product submissions in various markets outside the USA.

As an integrated pharmaceutical company, Aurobindo Pharma ranks among India's top pharmaceutical firms in terms of combined revenues. Exporting to over 150 countries globally, approximately 90% of its revenue comes from international ventures, serving esteemed multinational clientele.

Aurobindo Pharma’s facilities have approvals from major regulatory bodies across the world such as USFDA, EU GMP, UK MHRA, Health Canada, WHO and Brazil ANVISA.

Aurobindo Pharma operates five research centres spanning 16,000 square meters, along with two additional R&D centres in the USA. The company has a team of over 1,560 in-house scientists and analysts for product development.

Financial highlights

Aurobindo Pharma Limited's revenue from operations for FY23 stood at ₹24,855 crore, up 6% from ₹23,456 crore in FY22. The company recorded a PAT (profit after tax) of ₹1,928 crore in FY23 against ₹2,647 crore in FY22. In FY23, the earnings before interest, taxes, depreciation and amortisation (EBITDA) decreased to ₹3,758 crore from the previous year's ₹4,387 crore. The company's earnings per share (EPS) stood at ₹32.9 in FY23 compared to ₹45.19 in the previous financial year.

  • Chart
  • Fundamentals
  • Financials
  • F&O
  • Shareholdings
  • Events
  • Peers
  • News
  • FAQs

Aurobindo Pharma Share Price Chart

Please wait...

Aurobindo Pharma Key Indicators

P/E ratio
18.34
P/B ratio
2.06
ROE
10.06%
ROCE
11.56%
Dividend yield
0.41%
Debt/Equity ratio
0.14
EPS
32.43

Investment Checklist: (2/6)

not passed

Equity returns

not passed

Dividend returns

passed

Safety factor

NA

Growth factor

passed

Debt vs Equity

NA

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst Ratings:

Buy

Buy

76%

Hold

8%

Sell

16%

This analysis is based on the reviews of 25 experts in the last 7 days

Aurobindo Pharma Financial Ratios

  • Profitability

  • Operational

  • Valuation

Operating profit margin

26.63%

Net profit margin

17.82%

ROE

10.06%

ROA

6.66%

ROCE

11.56%

Aurobindo Pharma Shareholder returns

1 day
+1.36%
1 week
-4.61%
1 month
-7.94%
3 months
-6.55%
1 year
-11.74%
3 years
+115.24%
5 years
+40.05%

Revenue Statement

All values are in ₹ Crores (Cr)
RevenueNo Sort
Operating ProfitNo Sort
Net ProfitNo Sort
Mar-24
29,001.87
6,400.38
3,168.97
Mar-23
24,855.38
4,009.23
1,927.65
Mar-22
23,455.49
4,707.12
2,647.11
Mar-21
24,774.62
5,714.25
5,333.82

Cash Flow

All values are in ₹ Crores (Cr)
OperatingNo Sort
InvestingNo Sort
FinancingNo Sort
Mar-24
2,434.52
-4,255.95
800.42
Mar-23
2,386.75
-3,977.75
1814.41
Mar-22
5,016.48
-3,211.56
-2969.27
Mar-21
3,329.05
598.69
-1364.94

Balance Sheet

All values are in ₹ Crores (Cr)
Total AssetNo Sort
Total LiabilityNo Sort
Mar-24
43,858.87
14,008.07
Mar-23
39,212.50
12,360.65
Mar-22
33,633.13
9,059.08
Mar-21
33,401.31
11,472.32

Aurobindo Pharma Share Price History

DayOpenCloseChange %
20-Jun-25
₹1,087.90
₹1,097.20
+1.36%
19-Jun-25
₹1,106.00
₹1,082.50
-2.06%
18-Jun-25
₹1,109.70
₹1,105.30
-0.40%
17-Jun-25
₹1,145.40
₹1,109.70
-3.12%
16-Jun-25
₹1,152.10
₹1,145.40
-0.42%
13-Jun-25
₹1,141.00
₹1,150.20
-0.43%
12-Jun-25
₹1,164.80
₹1,155.20
-0.50%
11-Jun-25
₹1,194.30
₹1,161.00
-0.85%

Aurobindo Pharma Shareholding Pattern

CategoryMar 2025Dec 2024Sep 2024Jun 2024
Promoters
51.82%
51.82%
51.82%
51.80%
Foreign institutions-FII
15.33%
16.29%
16.59%
16.73%
Other domestic institutions
8.02%
7.39%
6.60%
5.60%
Retail and other
6.61%
6.69%
6.46%
6.70%
Mutual Funds
18.21%
17.81%
18.53%
19.17%

Corporate Actions

  • Dividend • ₹1.5/share

    Ex date 20 Feb 2024

    expand tab
  • Dividend • ₹3/share

    Ex date 20 Nov 2023

    expand tab

Stocks Similar to Aurobindo Pharma

PriceNo Sort
Change %No Sort
Abbott India₹31,055.00-₹565.00 (-1.79%)
Alkem Laboratories₹4,764.50-₹9.00 (-0.19%)
Biocon₹352.15+₹0.80 (0.23%)
Gland Pharma₹1,747.70+₹24.30 (1.41%)
GlaxoSmithKline Pharma₹3,172.50-₹41.00 (-1.28%)
Lupin₹1,928.00-₹20.00 (-1.03%)
Piramal Enterprises₹1,122.40-₹8.90 (-0.79%)
Torrent Pharmaceuticals₹3,165.10-₹2.10 (-0.07%)
Zydus Lifesciences₹952.15-₹4.95 (-0.52%)

Popular Stocks

PriceNo Sort
Change %No Sort
HDFC Bank₹1,948.90-₹15.80 (-0.8%)
Infosys₹1,584.50-₹38.40 (-2.37%)
ITC₹415.60-₹2.95 (-0.7%)
JIO FIN SERVICES LTD₹293.40-₹0.85 (-0.29%)
Reliance₹1,456.70-₹9.50 (-0.65%)
SBI₹790.15-₹6.00 (-0.75%)
Tata Motors₹671.00-₹5.20 (-0.77%)
Tata Power₹393.35+₹3.25 (0.83%)
Tata Steel₹152.34+₹0.37 (0.24%)
Wipro₹263.52-₹3.02 (-1.13%)

FAQs on Aurobindo Pharma

What is the share price of Aurobindo Pharma today?

chevron-up
Aurobindo Pharma share price is ₹ 1,100.30 as on 23 Jun, 2025 | 15:14 IST.

What are the high & low stock price of Aurobindo Pharma today?

chevron-up
Aurobindo Pharma stock price hit a high of ₹ 1,105.40 and low of ₹ 1,087.20 as on 23 Jun, 2025 | 15:14 IST.

What is the market cap of Aurobindo Pharma?

chevron-up
The market cap of Aurobindo Pharma is ₹ 63,725.56 Crores as on 23 Jun, 2025 | 15:14 IST.

What are the the 52-week high and low share prices of Aurobindo Pharma stock on the NSE?

chevron-up
52-week high stock Price of Aurobindo Pharma is ₹ 1,592.00 and Low Price is ₹ 1,010.00 as on 23 Jun, 2025 | 15:14 IST.

What are the stock symbols of Aurobindo Pharma?

chevron-up
The stock symbol of Aurobindo Pharma is NSE: AUROPHARMA on the NSE, BSE: 524804 on the BSE, and the ISIN is INE406A01037.

Can I buy Aurobindo Pharma shares on Holidays?

chevron-up
No, shares of Aurobindo Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Aurobindo Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.

What is the PE and PB ratio of Aurobindo Pharma?

chevron-up
The PE and PB ratio of Aurobindo Pharma is 18.34 and 2.06 respectively, as on 23 Jun, 2025 | 15:14 IST.

What are the returns on Aurobindo Pharma shares?

chevron-up
The historical returns for Aurobindo Pharma shares are -11.74 for 1 year, 115.24 for 3 year and 40.05 for 5 year.